News GSK reaches $2.2bn deal to buy food allergy biotech RAPT GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.